Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emmanuel Bachy

Showing results (71-80 of 176) with videos related to

Pageof 18
Sort By:
American Journal of Hematology|April 17, 2021
Outcome after hematopoietic stem cell transplantation in patients with extranodal natural killer/T-Cell lymphoma, nasal type: A French study from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)Laure Philippe Walter, Lucile Couronné, Jean-Philippe Jais, et al.
Blood|June 26, 2012
Early posttransplantation donor-derived invariant natural killer T-cell recovery predicts the occurrence of acute graft-versus-host disease and overall survivalMarie-Thérèse Rubio, Lucia Moreira-Teixeira, Emmanuel Bachy, et al.
Frontiers in Oncology|November 15, 2024
End-of-life management of multiple myeloma patients in the era of CD38 and immunotherapyPierre Sesques, Lionel Karlin, Emmanuel Massy, et al.
Blood Advances|January 5, 2024
Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortalityKai Rejeski, Yucai Wang, Doris K Hansen, et al.
Annals of Hematology|October 11, 2017
SMABcare study: subcutaneous monoclonal antibody in cancer care: cost-consequence analysis of subcutaneous rituximab in patients with follicular lymphomaEmilie Fargier, Florence Ranchon, Laure Huot, et al.
Hematological Oncology|January 19, 2020
Clinical characteristics and outcomes of relapsed follicular lymphoma after autologous stem cell transplantation in the rituximab eraPierre Sesques, Jessie Bourcier, Camille Golfier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 28, 2018
Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US CohortsClémentine Sarkozy, Matthew J Maurer, Brian K Link, et al.
Hematological Oncology|July 11, 2024
Evaluation of participation and recruitment bias in a prospective Real World Data in Lymphoma and Survival in Adults (REALYSA) cohort for newly diagnosed lymphoma patients over 1 year in a hematology department of teaching hospitalCaroline Le Lan, Aurélien Belot, Camille Golfier, et al.
The Lancet. Haematology|December 22, 2015
Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b/2 studyJehan Dupuis, Franck Morschhauser, Hervé Ghesquières, et al.
Haematologica|November 13, 2012
Lenalidomide as salvage treatment for multiple myeloma relapsing after allogeneic hematopoietic stem cell transplantation: a report from the French Society of Bone Marrow and Cellular TherapyTereza Coman, Emmanuel Bachy, Mauricette Michallet, et al.
Pageof 18

Showing results (71-80 of 176) with videos related to

Sort By:
Pageof 18
American Journal of Hematology|April 17, 2021
Outcome after hematopoietic stem cell transplantation in patients with extranodal natural killer/T-Cell lymphoma, nasal type: A French study from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)Laure Philippe Walter, Lucile Couronné, Jean-Philippe Jais, et al.
Blood|June 26, 2012
Early posttransplantation donor-derived invariant natural killer T-cell recovery predicts the occurrence of acute graft-versus-host disease and overall survivalMarie-Thérèse Rubio, Lucia Moreira-Teixeira, Emmanuel Bachy, et al.
Frontiers in Oncology|November 15, 2024
End-of-life management of multiple myeloma patients in the era of CD38 and immunotherapyPierre Sesques, Lionel Karlin, Emmanuel Massy, et al.
Blood Advances|January 5, 2024
Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortalityKai Rejeski, Yucai Wang, Doris K Hansen, et al.
Annals of Hematology|October 11, 2017
SMABcare study: subcutaneous monoclonal antibody in cancer care: cost-consequence analysis of subcutaneous rituximab in patients with follicular lymphomaEmilie Fargier, Florence Ranchon, Laure Huot, et al.
Hematological Oncology|January 19, 2020
Clinical characteristics and outcomes of relapsed follicular lymphoma after autologous stem cell transplantation in the rituximab eraPierre Sesques, Jessie Bourcier, Camille Golfier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 28, 2018
Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US CohortsClémentine Sarkozy, Matthew J Maurer, Brian K Link, et al.
Hematological Oncology|July 11, 2024
Evaluation of participation and recruitment bias in a prospective Real World Data in Lymphoma and Survival in Adults (REALYSA) cohort for newly diagnosed lymphoma patients over 1 year in a hematology department of teaching hospitalCaroline Le Lan, Aurélien Belot, Camille Golfier, et al.
The Lancet. Haematology|December 22, 2015
Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b/2 studyJehan Dupuis, Franck Morschhauser, Hervé Ghesquières, et al.
Haematologica|November 13, 2012
Lenalidomide as salvage treatment for multiple myeloma relapsing after allogeneic hematopoietic stem cell transplantation: a report from the French Society of Bone Marrow and Cellular TherapyTereza Coman, Emmanuel Bachy, Mauricette Michallet, et al.
Pageof 18